CHEMOPREVENTION OF GASTRIC DYSPLASIA

本项目通过以下方法解决胃癌的化学预防问题： 阻止慢性萎缩性胃炎和肠 化生，一种胃粘膜病变， 高风险。 它代表了在以下人群中继续进行的研究： 纳里尼奧，哥伦比亚，在那里对1788名受试者的队列进行了随访， 超过5年。 慢性萎缩性胃炎380例， 胃粘膜的肠上皮化生将进入一个 随机双盲临床试验测试抗氧化剂的作用 （抗坏血酸和β-胡萝卜素）以及抗幽门螺杆菌 治疗（次水杨酸铋和呋喃唑酮）。 14 c尿素呼气试验 将用于监测幽门螺杆菌复发 析因设计将是 利用。 将通过以下方式评价药物的作用 中间终点：癌前体的组织学（小肠 化生，结肠化生和发育不良），粘蛋白组织化学， 核仁组成区（AgNO 3-NORs）和复制带的形态 用PCN-cyclin单克隆抗体评价。 进展和 将比较干预之间每个参数的回归率 和安慰剂组。

This project addresses the issue of chemoprevention of gastric cancer by blocking the progression of chronic atrophic gastritis and intestinal metaplasia, a lesion of the gastric mucosa which identifies patients at high risk. It represents the continuation of studies in the population of Narino, Colombia, where a cohort of 1788 subjects has been followed for over 5 years. 380 patients with chronic atrophic gastritis and 740 with intestinal metaplasia of the gastric mucosa will be entered into a randomized double blind clinical trial testing the role of antioxidants (ascorbic acid and beta-carotene) as well as anti-Helicobacter pylori therapy (bismuth sub-salicylate and furazolidone). 14C urea breath test will be used to monitor H.p. relapses. A factorial design will be utilized. The effects of the agents will be evaluated with the following intermediate end-points: histology of cancer precursors (small intestinal metaplasia, colonic metaplasia and dysplasia), mucin histochemistry, nucleolar organizer regions (AgNO3-NORs) and morphology of replication zone evaluated with PCN-cyclin monoclonal antibodies. Progression and regression rates for each parameter will be compared between intervention and placebo groups.